Genetically engineered rat models for breast cancer

Breast Disease

Volumn 28, Issue , 2007, Pages 53-61

  Gould, Michael N ^a   Smits, Bart M G ^a   Cotroneo, Michelle S ^a   Haag, Jill D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RAS PROTEIN;

ANIMAL FOOD; ANIMAL HOUSING; ANIMAL MODEL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER MODEL; CANCER SUSCEPTIBILITY; COMPARATIVE ANATOMY; DNA DAMAGE; ENVIRONMENTAL FACTOR; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; HEREDITY; HORMONAL REGULATION; KNOCKOUT GENE; MOLECULAR GENETICS; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; RAT; RAT STRAIN; REVIEW; TRANSGENIC RAT; TUMOR SUPPRESSOR GENE;

EID: 36549075648     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2007-28106     Document Type: Review

References (58)

1. B. Wang, W.S. Kennan, J. Yasukawa-Barnes, M.J. Lindstrom and M.N. Gould, Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy, Cancer Res 52 (1992), 4102-4105.
2. S. Nandi, R.C. Guzman and J. Yang, Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis, Proc Natl Acad Sci USA 92 (1995), 3650-3657.
3. J. Russo, B.A. Gusterson, A.E. Rogers, I.H. Russo, S.R. Wellings and M.J. van Zwieten, Comparative study of human and rat mammary tumorigenesis, Lab Invest 62 (1990), 244-278.
4. J. Lazar, C. Moreno, H.J. Jacob and A.E. Kwitek, Impact of genomics on research in the rat, Genome Res 15 (2005) 1717-1728.
5. B.M. Smits and E. Cuppen, Rat genetics: The next episode, Trends Genet 22 (2006), 232-240.
6. Q. Shen and P.H. Brown, Transgenic mouse models for the prevention of breast cancer, Mutat Res 576 (2005), 93-110.
7. B. Charreau, L. Tesson, J.P. Soulillou, C. Pourcel and I. Anegon, Transgenesis in rats: Technical aspects and models, Transgenic Res 5 (1996), 223-234.
8. L.J. Mullins, G. Brooker and J.J. Mullins, Transgenesis in the rat, Methods Mol Biol 180 (2002), 255-270.
9. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
10. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244 (1989), 707-712.
11. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 344 (2001), 783-792.
12. L. Coussens, T.L. Yang-Feng, Y.C. Liao, E. Chen, A. Gray, J. McGrath, P.H. Seeburg, T.A. Libermann, J. Schlessinger, U. Francke et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science 230 (1985), 1132-1139.
13. P.P. Di Fiore, J.H. Pierce, M.H. Kraus, O. Segatto, C.R. King and S.A. Aaronson, erbB-2 is a potent oncogene when over-expressed in NIH/3T3 cells, Science 237 (1987), 178-182.
14. J.N. Hutchinson and W.J. Muller, Transgenic mouse models of human breast cancer, Oncogene 19 (2000), 6130-6137.
15. N.R. Lemoine, S. Staddon, C. Dickson, D.M. Barnes and W.J. Gullick, Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer, Oncogene 5 (1990), 237-239.
16. C.T. Guy, M.A. Webster, M. Schaller, T.J. Parsons, R.D. Cardiff and W.J. Muller, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc Natl Acad Sci USA 89 (1992), 10578-10582.
17. P.M. Siegel, D.L. Dankort, W.R. Hardy and W.J. Muller, Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors, Mol Cell Biol 14 (1994), 7068-7077.
18. B.R. Davies, A.M. Platt-Higgins, G. Schmidt and P.S. Rudland, Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats, Am J Pathol 155 (1999), 303-314.
19. P.A. Watson, K. Kim, K.S. Chen and M.N. Gould, Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene, Cancer Cell 2 (2002), 67-79.
20. J.L. Bos, Ras oncogenes in human cancer: A review, Cancer Res 49 (1989), 4682-4689.
21. S. Miyakis, G. Sourvinos and D.A. Spandidos, Differential expression and mutation of the ras family genes in human breast cancer, Biochem Biophys Res Commun 251 (1998), 609-612.
22. T. Clair, W.R. Miller and Y.S. Cho-Chung, Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer, Cancer Res 47 (1987), 5290-5293.
23. G.J. Clark and C.J. Der, Aberrant function of the Ras signal transduction pathway in human breast cancer, Breast Cancer Res Treat 35 (1995), 133-144.
24. M.E. DeBortoli, H. Abou-Issa, B.E. Haley and Y.S. Cho-Chung, Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents, Biochem Biophys Res Commun 127 (1985), 699-706.
25. P.H. Hand, A. Thor, D. Wunderlich, R. Muraro, A. Caruso and J. Schlom, Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas, Proc Natl Acad Sci USA 81 (1984), 5227-5231.
26. J. Lundy, R. Grimson, Y. Mishriki, S. Chao, S. Oravez, F. Fromowitz and M.V. Viola, Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients, J Clin Oncol 4 (1986), 1321-1325.
27. N. Ohuchi, A. Thor, D.L. Page, P.H. Hand, S.A. Halter and J. Schlom, Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues, Cancer Res 46 (1986), 2511-2519.
28. C. Dati, R. Muraca, O. Tazartes, S. Antoniotti, I. Perroteau, M. Giai, P. Cortese, P. Sismondi, G. Saglio and M. De Bortoli, c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome, Int J Cancer 47 (1991), 833-838.
29. U.J. Gohring, T. Schondorf, V.R. Kiecker, M. Becker, C. Kurbacher and A. Scharl, Immunohistochemical detection of H-ras protooncoprotern p21 indicates favorable prognosis in node-negative breast cancer patients, Tumour Biol 20 (1999), 173-183.
30. D.M. Watson, R.A. Elton, W.J. Jack, J.M. Dixon, U. Chetty and W.R. Miller, The H-ras oncogene product p21 and prognosis in human breast cancer, Breast Cancer Res Treat 17 (1991), 161-169.
31. E. Sinn, W. Muller, P. Pattengale, I. Tepler, R. Wallace and P. Leder, Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo, Cell 49 (1987), 465-475.
32. T.A. Thompson, J.D. Haag and M.N. Gould, ras gene mutations are absent in NMU-induced mammary carcinomas from aging rats, Carcinogenesis 21 (2000), 1917-1922.
33. M. Asamoto, T. Ochiya, H. Toriyama-Baba, T. Ota, T. Sekiya, M. Terada and H. Tsuda, Transgenic rats carrying human c-Ha-ras proto-oncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis, Carcinogenesis 21 (2000), 243-249.
34. H. Tsuda, M. Asamoto, T. Ochiya, H. Toriyama-Baba, A. Naito, T. Ota, T. Sekiya and M. Terada, High susceptibility of transgenic rats carrying the human c-Ha-ras proto-oncogene to chemically-induced mammary carcinogenesis, Mutat Res 477 (2001), 173-182.
35. B. Wang, W.S. Kennan, J. Yasukawa-Barnes, M.J. Lindstrom and M.N. Gould, Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains, Cancer Res 51 (1991), 5649-5654.
36. Y.T. Tat and M.N. Gould, The genetic penetrance of the activated neu oncogene for the induction of mammary cancer in vivo, Oncogene 14 (1997), 2701-2707.
37. M.N. Gould, The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors: A new model for the chemoprevention of premalignant and malignant lesions of the breast, J Cell Biochem Suppl 17G (1993), 66-72.
38. R.D. Cardiff, M.R. Anver, B.A. Gusterson, L. Hennighausen, R.A. Jensen, M.J. Merino, S. Rehm, J. Russo, F.A. Tavassoli, L.M. Wakefield, J.M. Ward and J.E. Green, The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting, Oncogene 19 (2000), 968-988.
39. S. Woditschka, J.D. Haag, J.L. Waller, D.M. Monson, A.A. Hitt, H.L. Brose, R. Hu, Y. Zheng, P.A. Watson, K. Kim, M.J. Lindstrom, B. Mau, V.E. Steele, R.A. Lubet and M.N. Gould, Neu-induced retroviral rat mammary carcinogenesis: A novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas, Cancer Res 66 (2006), 6884-6891.
40. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford and N. Wolmark, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 90 (1998), 1371-1388.
41. T.A. Thompson, K. Kim and M.N. Gould, Harvey ras results in a higher frequency of mammary carcinomas than Kirsten ras after direct retroviral transfer into the rat mammary gland, Cancer Res 58 (1998), 5097-5104.
42. K. Kim, M.J. Lindstrom and M.N. Gould, Regions of H- and K-ras that provide organ specificity/potency in mammary cancer induction, Cancer Res 62 (2002), 1241-1245.
43. W.D. Foulkes, Polygenic or pollyanna? Nat Med 8 (2002), 328-330.
44. K.L. Nathanson and B.L. Weber, "Other" breast cancer susceptibility genes: Searching for more holy grail, Hum Mol Genet 10 (2001), 715-720.
45. S.A. Narod and W.D. Foulkes, BRCA1 and BRCA2: 1994 and beyond, Nat Rev Cancer 4 (2004), 665-676.
46. N. Collins, R. McManus, R. Wooster, J. Mangion, S. Seal, S.R. Lakhani, W. Ormiston, P.A. Daly, D. Ford, D.F. Easton et al., Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13, Oncogene 10 (1995), 1673-1675.
47. S.A. Smith, D.F. Easton, D.G. Evans and B.A. Ponder, Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome, Nat Genet 2 (1992), 128-131.
48. B.M. Smits, J. Mudde, R.H. Plasterk and E. Cuppen, Target-selected mutagenesis of the rat, Genomics 83 (2004), 332-334.
49. Y. Zan, J.D. Haag, K.S. Chen, L.A. Shepel, D. Wigington, Y.R. Wang, R. Hu, C.C. Lopez-Guajardo, H.L. Brose, K.I. Porter, R.A. Leonard, A.A. Hitt, S.L. Schommer, A.F. Elegbede and M.N. Gould, Production of knockout rats using ENU mutagenesis and a yeast-based screening assay, Nat Biotechnol 21 (2003), 645-651.
50. B.M. Smits, J.B. Mudde, J. van de Belt, M. Verheul, J. Olivier, J. Homberg, V. Guryev, A.R. Cools, B.A. Ellenbroek, R.H. Plasterk and E. Cuppen, Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis, Pharmacogenet Genomics 16 (2006), 159-169.
51. B. Evers and J. Jonkers, Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects, Oncogene 25 (2006), 5885-5897.
52. M.S. Cotroneo, J.D. Haag, Y. Zan, C.C. Lopez, P. Thuwajit, G.V. Petukhova, R.D. Camerini-Otero, A. Gendron-Fitzpatrick, A.E. Griep, C.J. Murphy, R.R. Dubielzig and M.N. Gould, Characterizing a rat Brca2 knockout model, Oncogene 26 (2007), 1626-1635.
53. D.H. Yan, Y. Wen, L.K. Su, W. Xia, S.C. Wang, S. Zhang, L. Gan, D.F. Lee, B. Spohn, J.A. Frey, G.N. Hortobagyi and M.C. Hung, A delayed chemically induced tumorigenesis in Brca2 mutant mice, Oncogene 23 (2004), 1896-1901.
54. B.M. Smits and E. Cuppen, Rats go genomic, Genome Biol 7 (2006), 306.
55. J.M. Amos-Landgraf L.N. Kwong, C.M. Kendziorski, M. Reichelderfer, J. Torrealba, J. Weichert, J.D. Haag, K.S. Chen, J.L. Waller, M.N. Gould and W.F. Dove, A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer, Proc Natl Acad Sci USA 104 (2007), 4036-4041.
56. A.R. Moser, H.C. Pilot and W.F. Dove, A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse, Science 247 (1990), 322-324.
57. G.J. Rowse, S.R. Ritland and S.J. Gendler, Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis, Cancer Res 58 (1998), 2675-2679.
58. D.J. Samuelson, S.E. Hesselson, B.A. Aperavich, Y. Zan, J.D. Haag, A. Trentham-Dietz, J.M. Hampton, B. Mau, K.S. Chen, C. Baynes, K.T. Khaw, R. Luben, B. Perkins, M. Shah, P.D. Pharoah, A.M. Dunning, D.F. Easton, B.A. Ponder and M.N. Gould, Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk, Proc Natl Acad Sci USA 104 (2007), 6299-6304.